TI-RADS 3 Thyroid Nodule: What Does It Mean and What Happens Next?

A TI-RADS 3 (TR3) thyroid nodule is one that scored 3 points on the American College of Radiology (ACR) ultrasound system. TR3 sits in the middle of five levels, from TR1 to TR5, where higher levels reflect more features that raise concern. Under ACR criteria, a TR3 nodule is biopsied if it is 2.5 cm or larger and followed with ultrasound if it is 1.5 to 2.4 cm.

Thyroid nodules are common, and the US National Cancer Institute notes that only a small number are diagnosed as cancer. A TR3 score is a guide to what should happen next. It is not a diagnosis, and it cannot confirm or rule out cancer on its own.

This guide is for adults reading an existing thyroid ultrasound report. It explains the terms and helps you prepare questions. It cannot interpret your own scan or decide your follow-up.

Most thyroid nodules cause no symptoms. Contact your clinician sooner, rather than waiting for a routine scan date, if you notice a lump growing, new hoarseness or voice change, trouble swallowing, pain when swallowing, or breathing problems, including when lying flat. These can have many causes, but they need assessment.

If you have difficulty breathing, or rapidly increasing neck swelling after a biopsy, use local emergency services. MedlinePlus describes serious bleeding after thyroid FNA as rare, but bleeding that presses on the windpipe needs urgent help.

The ACR system gives points for five ultrasound features: composition (for example cystic, spongiform or solid), echogenicity (how bright or dark the nodule looks), shape, margins, and echogenic foci such as different types of calcification. The points are added together to give a risk level.

In the ACR reporting template, TR1 is 0 points, TR2 is 2 points, TR3 is 3 points and TR4 is 4 to 6 points. Higher totals place a nodule in TR5. A TR3 total can be reached in different ways, so two TR3 nodules may not look the same.

Imaging can show a nodule but often cannot tell whether it is benign or cancerous, as RadiologyInfo explains. That is why the ACR pairs the score with size: the score suggests how closely to look, and the size sets the threshold for action.

Other thyroid scoring systems also use the name TIRADS, and their numbers do not always match the ACR categories. Check which system your report names before comparing your result with any chart.

The ACR thyroid ultrasound reporting template sets out these recommendations by category and maximum size. Your report should state the largest dimension in centimetres.

• TR3, 2.5 cm or larger: fine-needle aspiration (FNA) biopsy is recommended.
• TR3, 1.5 to 2.4 cm: follow-up ultrasound at 1, 3 and 5 years.
• TR3, under 1.5 cm: the ACR chart sets no biopsy or follow-up threshold for this size.
• TR1 and TR2: no FNA or follow-up under ACR criteria.
• Significant growth, in the template's terms: an increase of 20% or more in two dimensions, with a minimum increase of 2 mm. A change in features or category is also recorded.

At each follow-up ultrasound, the radiologist measures the nodule again and compares it with earlier images. The ACR template asks the reporter to record three things: whether the size has changed significantly, whether its features have changed, and whether its TI-RADS category has changed.

A stable nodule usually continues on the agreed schedule. Significant growth or a move to a higher category is a reason for your clinician to review the plan, which may include considering FNA. Keep copies of every report so that each new scan can be compared with the last, especially if you change hospital or clinic.

A scan done elsewhere may use slightly different wording. If the new report does not mention a comparison, ask whether the earlier images were available to the person reading it.

FNA is considered when a nodule's category and size cross the ACR threshold, or when your clinician has other reasons for concern. A thin needle collects cells from the nodule, usually with ultrasound guidance. RadiologyInfo says the procedure usually takes less than 30 minutes and is typically done as an outpatient.

A pathologist examines the sample. MedlinePlus describes results as benign or showing cancer; sometimes the sample is too limited for a conclusion and the biopsy may need repeating. Tell the team about any blood thinners, but do not stop a prescribed medicine unless the team instructs you to.

Clinicians do not rely on the ultrasound score alone. MedlinePlus lists a TSH blood test and other thyroid function tests as part of the assessment, and sometimes a thyroid nuclear scan. Nodules that make thyroid hormone can cause overactive thyroid symptoms such as a fast pulse or weight loss.

Personal history matters too. MedlinePlus describes a nodule as more likely to be cancer with a family history of thyroid cancer, past radiation to the head or neck, voice change, or a nodule that is hard or fixed. Being male, or younger than 20 or older than 70, is also listed. Tell your clinician about any of these, even if the report does not mention them.

Bring the full ultrasound report, not just a summary line, and any earlier scans. These questions can help you leave with a clear plan.

• Which scoring system does the report use, and which features produced the TR3 total?
• What is the nodule's maximum size, and was it compared with any earlier scan?
• Does my size fall into the biopsy, follow-up or no-follow-up group, and does anything in my history change that?
• Have my thyroid blood tests been checked, and what did they show?
• When is the next scan, who will book it, and what would make you bring it forward?
• If FNA is advised, what will happen if the sample is non-diagnostic?

On SameCase, patients and verified doctors share de-identified cases. Reading how others with a TR3 nodule of a similar size were followed up can show which questions they asked and which details turned out to matter, such as earlier scans or thyroid blood tests.

Other people's cases cannot tell you what your nodule is or what your plan should be. Use them to sharpen your questions, then take those questions to the clinician who has your full report and history.